Tesamorelin / Ipamorelin Blend
Also known as: Tesamorelin & Ipamorelin, Tesamorelin, Ipamorelin
A research blend combining the visceral-fat-reducing GHRH analog Tesamorelin with the selective ghrelin agonist Ipamorelin. It is studied for synergistic GH release with a favorable metabolic profile.
Last updated
Mechanism of Action
Tesamorelin is a stabilized analog of GHRH that binds the pituitary GHRH receptor to increase pulsatile growth hormone secretion and has been clinically shown to reduce visceral adipose tissue. Ipamorelin selectively activates the GHS-R1a (ghrelin) receptor to evoke an additional GH pulse without significantly raising cortisol or prolactin. Acting through two distinct receptors, the combination produces a synergistic GH response while Tesamorelin contributes targeted lipolytic effects on visceral fat.
- Half-life
- Mixed: Tesamorelin ~26-38 minutes, Ipamorelin ~2 hours
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for synergistic GH release
- Investigated for visceral adipose tissue reduction
- Examined for improved body composition and lean mass
- Researched for enhanced recovery
- Studied for IGF-1 elevation through natural pathways
- Investigated for improved sleep quality
Potential Side Effects
- Injection-site redness, itching, or swelling
- Water retention and joint or muscle aches
- Tingling or numbness in extremities
- Transient flushing or lightheadedness
- Modest appetite increase
Common Dosing
In the research literature, blends are studied at approximately 100-300 mcg of each component per administration, 1-2 times daily, often pre-sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or ghrelin-receptor analogs
Tesamorelin / CJC-1295 / Ipamorelin Blend
A potent three-part research blend pairing two GHRH analogs, Tesamorelin and CJC-1295 (No DAC), with the selective ghrelin agonist Ipamorelin. It is studied for strong synergistic GH release and visceral fat reduction.
Sermorelin / Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
Fragment 176-191 / CJC-1295 / Ipamorelin Blend
A three-part research blend combining the lipolytic HGH Fragment 176-191 with the GHRH analog CJC-1295 (No DAC) and the selective ghrelin-receptor agonist Ipamorelin. It is studied for its combined effect on endogenous growth hormone release and fat metabolism.
- View
Ipamorelin, the first selective growth hormone secretagogue
1998
- View
Metabolic effects of a growth hormone-releasing factor in patients with HIV
2007
- View
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
2010
- View
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
2019